The collaboration is in line with Orexo's strategy to broaden the use of its powder-based drug delivery technology AmorphOX®. Abera is a developer of mucosal vaccines and has several preclinical vaccine candidates based on Abera's innovative vaccine platform. The AmorphOX technology has...
Hence then, the article about orexo enters into collaboration with abera to develop nasal powder vaccines based on the amorphox technology was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Orexo enters into collaboration with Abera to develop nasal powder vaccines based on the AmorphOX technology )
Also on site :
- ‘Bachelor’ Alum Lauren Luyendyk Calls Out Alex Cooper Over Comments About Her Daughter: ‘Took It Too Far’
- 1991 Primetime Soap Finale Ranked Among 'Most Unforgettable' of All Time Aired Exactly 35 Years Ago Today
- Alternativa Film Festival Wraps in Medellín, Prizes ‘Runa Simi,’ ‘9-Month Contract,’ ‘A Useful Ghost’